Clinical Validation of Standard Q COVID-19 Antigen and IgM/IgG Combo Kit Assay at a Tertiary Care Center in Northern India

Abstract

Background Expansion of the testing capacities for severe acute respiratory syndrome-coronavirus-2 is an important issue in the face of ever-increasing case load. So, there is need of point-of-care diagnostic tests in the existing laboratory capacities for early treatment, isolation, and clinical decision making, especially in resource limited settings. Materials and Methods This prospective cohort study was conducted at Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi. Nasopharyngeal samples and blood samples were collected for antigen and antibody testing. Rapid antigen test was performed as per the kit's instructions. The performance of the kit was compared with the gold standard reverse transcription polymerase chain reaction (RT-PCR) testing. Results Eighty-eight out of 110 patients tested positive by RT-PCR for coronavirus disease 2019 in last 48 to 72 hours were included in the study. Overall, the sensitivity of combined antibody test was 52%, antigen test 26%, and combined sensitivity of both antigen and antibody was 72.7%, respectively. Conclusion The combo kit needs to be used with caution in low prevalence settings, where cases may be missed.

Neutralizing immunity against coronaviruses in Tanzanian health care workers

“…We used STANDARD Q COVID-19 IgM/IgG plus antibody test kit (SD Biosensor) to detect SARS-CoV-2 IgG and IgM from plasma samples of study participants. This kit is a rapid immunochromatography test designed for the qualitative presumptive detection of anti nucleocapsid (N) and antispike –RBD specific SARS-CoV-2 IgM and IgG 17 . Briefly, 10 µL of plasma was added to the specimen well followed by 3 drops of buffer.…”